All News
APLAR 2025: What’s New in RA Management?
The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making while reinforcing the importance of treat-to-target principles in RA.
Read Article
Addressing Disparities and Unequal Burdens in ILD
Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not fall evenly. We are increasingly learning that where you live, who you are, and the resources available to you, can strongly influence how ILD develops and worsens. Understanding these disparities is not about pointing fingers. Rather, it is about uncovering opportunities to deliver better, fairer care.
Read Article
Rheumatoid Arthritis ILD Complications
https://t.co/gAZCGTwHLB https://t.co/qcMmDuxXYx
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA
A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).
https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU
Dr. John Cush RheumNow ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar
📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST
An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies.
Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator
https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH
Dr. John Cush RheumNow ( View Tweet)
Ellen Gravallese update on RA pathogenesis
Her take on RA interception studies
“While drug repurposing has not proven capable of preventing transition from Pre RA to RA, we need to better understand disease mechanisms to offer other interventions”
@RheumNow #APLAR25 @APLAR_org https://t.co/d39ihVvWyA
Aurelie Najm AurelieRheumo ( View Tweet)
One of the most impt updates recommended to add a bDMARD if tx target is not achieved by the 1st csDMARD (no more prognostic stratification)
But, accdg to Dr. Smolen, adding a 2nd csDMARD should still be considered especially in resource-limited countries.
@RheumNow #APLAR25 https://t.co/ZQiviGcrYp
sheila RHEUMarampa ( View Tweet)
Dr. Josef Smolen discusses 2025 EULAR updates for RA.
He highlighted the importance of OP A - that tx should be a shared decision making between px and rheuma in order to ensure better care and disease control.
@RheumNow #aplar25 #APLAR25 https://t.co/KOJbiK87TS
sheila RHEUMarampa ( View Tweet)
Methotrexate significantly lowers Systolic BP
Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs. https://t.co/HDnDWahuul
Dr. John Cush RheumNow ( View Tweet)
SSc-ILD ABs & LESSONS:
30% of won't progress.
Triple negatives (ATA, ACA, ARA) wont progress.
Males & diffuse dz > predictive than Abs.
Great read on if Abs are biomarkers to predict Rx effect. https://t.co/YcZt4aAvL0 https://t.co/wOknKRfRHf
Dr. John Cush RheumNow ( View Tweet)
ACR Concerns on the Scientific Integrity at the CDC
On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W
Dr. John Cush RheumNow ( View Tweet)
Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd
Dr. John Cush RheumNow ( View Tweet)
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/DPgDQsCWK9
Dr. John Cush RheumNow ( View Tweet)
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease
RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/sSzMvDUMf5
Dr. John Cush RheumNow ( View Tweet)
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/QLod6uj2Dj
Dr. John Cush RheumNow ( View Tweet)
Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/8IWXWZmWgE
Dr. John Cush RheumNow ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar
📅 Sept 9 | ⏰ 7PM EST
An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies.
Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator
https://t.co/2F3sOjqHtr
#ILD https://t.co/KaVL1pUdCh
Dr. John Cush RheumNow ( View Tweet)
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/WFwavo32rB
Dr. John Cush RheumNow ( View Tweet)
Crepitus Does Not Predict Earlier/Worse OA
Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis.
https://t.co/bu8dgzcqdv https://t.co/CnSjv6cor9
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Be Careful What You Look For
Dr. Bryant England, University of Nebraska, presents this QD Clinic, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/avxw86CGqu https://t.co/5SH3p05Rlf
Links:
Dr. John Cush RheumNow ( View Tweet)
